10.08.2011 • News

Myriad Genetics Q4 Profit Falls

Myriad Genetics reported net income for the fourth quarter of $26.0 million or $0.30 per share, compared to $53.3 million or $0.54 per share for the year-ago quarter.

The latest quarter results include a $16.1 million income tax expense recorded for accounting purposes, while the year-ago quarter results included no tax expense and a one-time income tax benefit of $14.6 million.

Total revenue for the fourth quarter rose to $107.41 million from $93.93 million a year earlier.

Analysts polled by Thomson Reuters expected the company to earn $0.29 per share on revenue of $104.43 million for the fourth quarter.

For fiscal year 2012, the company forecast total revenue of $445 million to $465 million and earnings of $1.20 to $1.25 per share. Analysts currently expect the company to earn $1.26 per share on revenue of $453.80 million for the fiscal year 2012.

 

Interview

Leading Transformation
The Path to Sustainable Growth

Leading Transformation

As Executive Vice President of International Chemicals since early 2024, Antje Gerber has been steering Sasol through a pivotal reset—focused on resilience, innovation, and bold sustainability goals.

Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read